PTC Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PTC Therapeutics (NASDAQ: PTCT) will present at the Evercore ISI 3rd Annual HealthCONx Conference on December 1, 2020, at 11:45 a.m. ET. This presentation, featuring a company overview, will be available via live webcast on PTC's website, with an archived version accessible for 30 days. PTC Therapeutics is a global biopharmaceutical company specializing in innovative treatments for rare disorders, emphasizing its commitment to meeting unmet medical needs through a diversified pipeline of transformative medicines.
Details
News Market Reaction – PTCT
The recorded move for PTCT in the trading session of this news was +1.78%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH PLAINFIELD, N.J., Nov. 19, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1st at 11:45 a.m. ET.
The presentation will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at www.ptcbio.com and will be archived for 30 days following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.
About PTC Therapeutics, Inc.
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.
FOR MORE INFORMATION PLEASE CONTACT: | |
Media: | Investors: |
Jane Baj | Lisa Hayes |
+1 (908) 912-9167 | +1 (732) 354-8687 |
jbaj@ptcbio.com | lhayes@ptcbio.com |
View original content:http://www.prnewswire.com/news-releases/ptc-therapeutics-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference-301174099.html
SOURCE PTC Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.